A novel, selective BCR-ABL inhibitor. More potent than imatinib against wild-type BCR-ABL (IC50 < 30 nM)1. Induces apoptosis2.
1) Weisberg et al. (2006), AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL; Br J. Cancer, 94 1765
2) Verstovsek et al. (2006), Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells; Ann. Neurol., 75 209